SCI reúne recursos sobre inmunidad y SARS-CoV-2

116. Impacto de la pandemia COVID-19 en los tratamientos inmunomoduladores/inmunosupresores en dermatología: actitudes de los pacientes y los dermatólogos en Argentina. Actas Dermosifiliogr. 2020 Apr 29; doi: 10.1016/j.ad.2020.04.004
115. Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection. Antiviral Res. 2020 Apr 29:104811; doi: 10.1016/j.antiviral.2020.104811
114. SARS-CoV2 entry and spread in the lymphatic drainage system of the brain. Brain Behav Immun. 2020 Apr 29; doi: 10.1016/j.bbi.2020.04.080
113. Perforación intestinal en paciente covid-19 en tratamiento con tocilizumab y corticoides. A propósito de un caso. Cir Esp. 2020 Apr 29; doi: 10.1016/j.ciresp.2020.04.030
112. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450; doi: 10.1016/j.clim.2020.108450
111. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach. Inform Med Unlocked. 2020; doi: 10.1016/j.imu.2020.100338
110. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol. 2020; doi: 10.1016/j.jaci.2020.04.029
109. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020; doi: 10.1016/j.jaci.2020.04.027
108. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19. Cancer Immunol Immunother. 2020 Apr 28:1–2; doi: 10.1007/s00262-020-02580-1
107. Protective immunity after COVID-19 has been questioned: what can we do without SARS-CoV-2-IgG detection? Cell Immunol. 2020; doi: 10.1016/j.cellimm.2020.104114
106. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients. Cell Mol Immunol. 2020; doi: 10.1038/s41423-020-0447-2
105. Proposed use of thalidomide for the cytokstorm of COVID-19. Clin Dermatol. 2020; doi: 10.1016/j.clindermatol.2020.04.015
104. Role of increasing the aerobic capacity on improving the function of immune and respiratory systems in patients with coronavirus (COVID-19): A review. Diabetes Metab Syndr. 2020; doi: 10.1016/j.dsx.2020.04.038
103. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement. J Clin Virol. 2020 Jun;127:104388.
102. Detección viral y respuesta serológica en pacientes críticos intubados con SARS-CoV-2. Implicaciones para retirada de aislamiento. Med Intensiva. 2020; doi: 10.1016/j.medin.2020.04.014
101. Cancer therapy tool informs COVID-19 vaccines. Nat Rev Immunol. 2020; doi: 10.1038/s41577-020-0326-1
100. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020; doi: 10.1038/s41577-020-0323-4
99. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; doi: 10.1038/s41577-020-0311-8
98. Neutralizing antibody response in mild COVID-19. Nat Rev Immunol. 2020; doi: 10.1038/s41577-020-0325-2
97. An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design. Vaccine. 2020; doi: 10.1016/j.vaccine.2020.04.034
96. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020 Apr 18:102763; doi: 10.1016/j.ebiom.2020.102763.
95.Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. Eur Urol. 2020 Apr 18; doi: 10.1016/j.eururo.2020.03.039.
94. Guillain-Barré Syndrome associated with SARS-CoV-2 infection. IDCases. 2020 Apr 18:e00771; doi: 10.1016/j.idcr.2020.e00771.
93. The immunological case for staying active during the COVID-19 pandemic. Brain Behav Immun. 2020 Apr 18; doi: 10.1016/j.bbi.2020.04.041.
92. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020 May;87(3):191–193.
91. COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights. Int Ophthalmol. 2020 Apr 20:1–4; doi: 10.1007/s10792-020-01389-2.
90. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia. J Infect. 2020 Apr 20; doi: 10.1016/j.jinf.2020.04.001.
89. A short review on antibody therapy for COVID-19. New Microbes New Infect. 2020 Apr 20:100682; doi: 10.1016/j.nmni.2020.100682.
88. Chloroquine reduces Th17 cell differentiation by stimulating T-bet expression in T cells. Cell Mol Immunol. 2020 Apr 20;1–2; doi: 10.1038/s41423-020-0432-9.
87. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020 Apr 20:1–3; doi: 10.1038/s41423-020-0426-7.
86. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep. 2020;22(5):32.
85. Infección por SARS-CoV-2 asociada a diplopía y anticuerpos antirreceptor de acetilcolina. Neurologia. 2020 Apr 18; doi: 10.1016/j.nrl.2020.04.003.